Core Viewpoint - The company has received approval for its new drug, Methylthio-2-aminobutane injection, which is indicated for various medical conditions, enhancing its product portfolio and potential market reach [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has obtained the drug registration certificate from the National Medical Products Administration for Methylthio-2-aminobutane injection [1] - The approved drug is an anticholinesterase agent, used to counteract the residual muscle relaxation effects of non-depolarizing muscle relaxants at the end of surgery [1] Group 2: Product Indications - The indications for Methylthio-2-aminobutane injection include treatment for myasthenia gravis, postoperative functional intestinal distension, and urinary retention [1]

关于全资子公司获得甲硫酸新斯的明注射液注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州市联瑞 制药有限公司于近日收到国家药品监督管理局核准签发的关于甲硫酸新斯的明 注射液的《药品注册证书》，现将有关事项公告如下： 一、药品注册证书主要信息 证券代码：300723 证券简称：一品红 公告编号：2025-065 一品红药业集团股份有限公司 药品通用名称：甲硫酸新斯的明注射液 英文名/拉丁名：Neostigmine Methylsulfate Injection 主要成份：甲硫酸新斯的明 剂 型：注射剂 注册分类：化学药品 3 类 规 格：4ml:2mg 药品注册标准编号：YBH25642025 药品有效期：24 个月 生产企业：广州市联瑞制药有限公司 生产企业地址：广州市南沙区万顷沙镇同发路 2 号 药品批准文号：国药准字 H20255676 药品批准文号有效期：至 2030 年 10 月 13 日 申请事项：药品注册（境内生产） 包装规格： 5 支/盒 处方药/非处方药：处方药 审批结论 ...

Core Viewpoint - The company Yipinhong (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has received the drug registration certificate for Methacholine Chloride Injection from the National Medical Products Administration [1] Group 1 - The approved product, Methacholine Chloride Injection, is indicated for use as an anticholinesterase agent [1] - The injection is used to counteract the residual muscle relaxation effects of non-depolarizing muscle relaxants at the end of surgery, as well as for conditions such as myasthenia gravis, postoperative functional bowel distension, and urinary retention [1]

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 216.94%, but recent declines in the short term indicate potential market concerns [1][2]. Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002, with its listing date on November 16, 2017. The company focuses on the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals [1]. - The main business revenue composition includes children's medicine (61.12%), chronic disease medicine (22.71%), and others (16.17%) [1]. Financial Performance - For the first half of 2025, Yipinhong reported an operating income of 584 million yuan, a year-on-year decrease of 36.02%. The net profit attributable to the parent company was -73.54 million yuan, a year-on-year decrease of 258.30% [2]. - Since its A-share listing, Yipinhong has distributed a total of 335 million yuan in dividends, with 151 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, the number of Yipinhong's shareholders was 18,900, a decrease of 11.34% from the previous period. The average circulating shares per person increased by 12.79% to 22,055 shares [2]. - As of June 30, 2025, Yipinhong's top ten circulating shareholders included a new entrant, E Fund Medical Healthcare Industry Mixed A, holding 4.3661 million shares, while Hong Kong Central Clearing Limited exited the top ten list [3]. Market Activity - On October 15, Yipinhong's stock rose by 2.06%, reaching 54.07 yuan per share, with a trading volume of 159 million yuan and a turnover rate of 0.71%. The total market capitalization stood at 24.423 billion yuan [1]. - The stock has experienced significant fluctuations, with a recent decline of 9.02% over the last five trading days and a 21.13% drop over the past 20 days [1].

Market Overview - The chemical pharmaceutical sector experienced a decline of 2.62% on October 14, with Yipinhong leading the drop [1] - The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1] Stock Performance - Notable gainers included: - Asia-Pacific Pharmaceutical (002370) with a closing price of 6.24, up 10.05% [1] - Duorui Pharmaceutical (301075) at 42.06, up 4.94% [1] - Deyuan Pharmaceutical (920735) at 37.78, up 3.00% [1] - Major decliners included: - Yipinhong (300723) at 52.98, down 14.30% [2] - Betta Pharmaceuticals (300558) at 58.34, down 10.63% [2] - Zerui Pharmaceutical (688266) at 93.60, down 7.60% [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 2.271 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.481 billion yuan [2][3] - The top stocks by net inflow from institutional investors included: - Asia-Pacific Pharmaceutical with a net inflow of 53.03 million yuan [3] - Xiangrikui (300111) with a net inflow of 45.54 million yuan [3] - Conversely, Yipinhong experienced a significant net outflow of 979 million yuan from institutional investors [2][3]

Group 1 - The core viewpoint of the news is that Yipinhong Pharmaceutical Group Co., Ltd. has seen a significant stock price increase of 5.35%, reaching 61.40 CNY per share, with a total market capitalization of 27.734 billion CNY [1] - Yipinhong's main business involves the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals, with revenue composition being 61.12% from children's medicine, 22.71% from chronic disease medicine, and 16.17% from other products [1] Group 2 - From the perspective of fund holdings, Yipinhong is a significant investment for Huabao Fund, with its Huabao Medical Biotechnology Mixed A Fund holding 373,000 shares, accounting for 3.59% of the fund's net value, making it the ninth largest holding [2] - The Huabao Medical Biotechnology Mixed A Fund has achieved a year-to-date return of 57.32%, ranking 622 out of 8234 in its category, and a one-year return of 41.08%, ranking 1680 out of 8083 [2] Group 3 - The fund manager of Huabao Medical Biotechnology Mixed A Fund is Zhang Jintao, who has been in the position for nearly 10 years, with the fund's total asset size at 1.202 billion CNY [3] - During Zhang's tenure, the best fund return was 62.24%, while the worst return was -14.23% [3]

Group 1 - The company Yipinhong (300723) reported that as of September 30, 2025, the total number of shareholders is 18,937 [1]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）2024 年员工持股计划（以 下简称"本次员工持股计划"）第一个锁定期于 2025 年 10 月 10 日届满。根据 《关于上市公司实施员工持股计划试点的指导意见》及《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》等相关规定，现将本次员 工持股计划锁定期届满情况公告如下： 证券代码：300723 证券简称：一品红 公告编号：2025-064 一品红药业集团股份有限公司 关于 2024 年员工持股计划第一个锁定期届满的提示性公告 本次员工持股计划的股票来源为公司回购专用证券账户回购的公司 A 股普 通股股票。本次员工持股计划通过非交易过户的方式过户了 5,116,105 股公司股 票，占公司目前总股本的 1.13%，该部分股票全部来源于上述回购股份。 2、公司季度报告、业绩预告、业绩快报公告前 5 日内； 3、自可能对本公司股票及其衍生品种交易价格产生较大影响的重大事件发 生之日或者进入决策程序之日至依法披露之日； 4、中国证监会及证券交易所 ...

Core Points - The Shanghai Composite Index is at 3927.63 points, slightly down by 0.16%, with a total trading volume of 1.2446 trillion yuan [1] - A total of 181 A-shares have surpassed the half-year line, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - Li Min Co., Ltd. (002734) has a deviation rate of 4.31% with a price increase of 6.27% [1] - Yuanda Environmental Protection (600292) shows a deviation rate of 3.35% and a price increase of 3.93% [1] - Oriental Carbon (920175) has a deviation rate of 3.28% with an 8.17% price increase [1] Trading Activity - The total trading volume for A-shares today is reported at 1.2446 trillion yuan [1] - The stocks with the smallest deviation rates include Lian Ke Technology, Lingkang Pharmaceutical, and Publishing Media, which have just crossed the half-year line [1] Deviation Rate Rankings - The top stocks with the highest deviation rates include: - Li Min Co., Ltd. (002734) at 4.31% - Yuanda Environmental Protection (600292) at 3.35% - Oriental Carbon (920175) at 3.28% [1] - Other notable stocks with significant price increases and deviation rates include: - Han Commercial Group (600774) at 3.19% - Rui Pu Biological (300119) at 2.99% [1]

Group 1 - Zhiguang Electric plans to acquire minority stakes in its subsidiary Zhiguang Energy Storage through a combination of share issuance and cash payment, leading to a temporary suspension of its stock trading for up to 10 trading days [1] - Guangbo Co. has been awarded a procurement project by the State Grid Corporation of China, confirming its status as one of the successful bidders for office and industrial supplies [2] - Dongguan Holdings announced the resignation of its chairman Wang Chong'en due to work changes, with Lin Yongsen appointed as the interim chairman [2] Group 2 - *ST Tianmao's stock will be delisted on September 30, 2025, following the Shenzhen Stock Exchange's decision to terminate its listing [3] - Salt Lake Co. has entered the trial production phase for its 40,000 tons/year integrated lithium salt project, successfully producing qualified battery-grade lithium carbonate [5] - Xindazheng plans to adjust its share repurchase price limit from 13.78 yuan to 16.79 yuan per share, maintaining a total repurchase fund of 10 million to 20 million yuan [7] Group 3 - Xindazheng intends to acquire 75.15% of Jiaxin Liheng's equity through share issuance and cash payment, with the transaction price yet to be determined [9] - Koli'er's actual controller plans to reduce his stake by up to 2% of the company's total shares due to funding needs [11] - United Precision's two actual controllers plan to collectively reduce their stake by up to 3% of the company's total shares for personal financial reasons [13] Group 4 - Yipinhong's subsidiary has received a drug registration certificate for L-carnitine oral solution, which is classified as a chemical drug [15] - Tiancheng Self-Control plans to establish a wholly-owned subsidiary in Japan and invest in a warehouse and production base with a budget of up to 10 million yuan [17] - Ningbo Huaxiang's joint venture has obtained a patent license from Jilin University for PEEK technology, which will enhance its R&D capabilities [21] Group 5 - Bright Dairy's subsidiary Synlait Milk Limited plans to sell its North Island assets to Abbott for $170 million, aiming to focus on core business development [23] - Nanjing Pharmaceutical has signed a strategic investment agreement with Guangzhou Baiyunshan Pharmaceutical Group, with the latter acquiring 11.04% of Nanjing Pharmaceutical's shares [24] - Guoxing Optoelectronics' application for a private placement of A-shares has been accepted by the Shenzhen Stock Exchange [25] Group 6 - Hailianxun has received approval from the China Securities Regulatory Commission for its plan to merge with Hangqilun B through a share exchange [27] - CITIC Bank's risk director Hu Gang has resigned, with Jin Xinian appointed as the new risk director pending regulatory approval [29]